Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients

NCT04541485 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.

NCT NCT04541485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Phase
Phase 1
Overall status
Terminated
Start date
December 4, 2020
Completion date
March 23, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 patients